Francis Knuettel II 4
4 · Chromocell Therapeutics Corp · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Francis Knuettel II
CFO, Treas & Secty
Transactions
- Award
Stock Options
2024-06-14+324,000→ 376,778 totalExercise: $1.30Exp: 2034-06-14→ Common Stock (324,000 underlying) - Award
Stock Options
2024-06-14+27,778→ 52,778 total(indirect: By LLC)Exercise: $1.30From: 2024-06-14Exp: 2034-06-14→ Common Stock (27,778 underlying)
Footnotes (3)
- [F1]On June 14, 2024, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $1.30 per share, which were fully vested.
- [F2]The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
- [F3]On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.